TKM-100802 for Injection + Placebo

Phase 1Terminated
0 watching 0 views this week๐Ÿ’ค Quiet
28
Hype Score

Development Stage

โœ“
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Ebola Virus Infection

Conditions

Ebola Virus Infection

Trial Timeline

Jan 1, 2014 โ†’ Jul 1, 2015

About TKM-100802 for Injection + Placebo

TKM-100802 for Injection + Placebo is a phase 1 stage product being developed by Arbutus Biopharma for Ebola Virus Infection. The current trial status is terminated. This product is registered under clinical trial identifier NCT02041715. Target conditions include Ebola Virus Infection.

Hype Score Breakdown

Clinical
10
Activity
5
Company
5
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT02041715Phase 1Terminated

Competing Products

20 competing products in Ebola Virus Infection

See all competitors